Pharmaceuticals
Biologics

Novartis pelacarsen Phase III trial fails to cut CV events

The Lp(a)HORIZON outcomes trial in 8,323 patients met its Lp(a)-lowering goal but did not reduce the composite cardiovascular endpoint versus
The Lp(a)HORIZON outcomes trial in 8,323 patients met its Lp(a)-lowering goal but did not reduce the composite cardiovascular endpoint versus
The Biotech Times Editorial Team  · 
Medical Devices
Diagnostics
Biotech

Magrabi Health earns first global SRC Network of Excellence in

The Saudi-founded eye care group becomes the first healthcare network worldwide to receive the Surgical Review Corporation's specialist ophthalmology network
The Saudi-founded eye care group becomes the first healthcare network worldwide to receive the Surgical Review Corporation's specialist ophthalmology network
The Biotech Times Editorial Team  · 
Medical Devices

ONWARD Medical starts EIGER implant study for spinal cord injury

The Eindhoven neurotechnology company has performed the first ARC-IM implant in its EIGER feasibility study, which will enrol up to 12 participants across subacute
The Eindhoven neurotechnology company has performed the first ARC-IM implant in its EIGER feasibility study, which will enrol up to 12 participants across subacute
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Canada's CDA-AMC backs conditional reimbursement for Yorvipath

Palopegteriparatide gains a positive reimbursement recommendation in Canada for adults with chronic hypoparathyroidism inadequately controlled on standard therapy.
Palopegteriparatide gains a positive reimbursement recommendation in Canada for adults with chronic hypoparathyroidism inadequately controlled on standard therapy.
The Biotech Times Editorial Team  · 
Biologics
Pharmaceuticals

Climb Bio CLYM116 Phase 1 data back every-12-week dosing in IgAN

Phase 1 data show CLYM116 achieved near-complete APRIL suppression and a 29-day half-life, supporting quarterly dosing in IgA nephropathy.
Phase 1 data show CLYM116 achieved near-complete APRIL suppression and a 29-day half-life, supporting quarterly dosing in IgA nephropathy.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics
Cell & Gene Therapy

Eledon files IND for islet cell transplant trial as Phase 3 nears

Eledon Pharmaceuticals has submitted an IND for a registrational islet cell transplant study of tegoprubart, while reaffirming its Q4 2026 Phase 3 kidney trial start.
Eledon Pharmaceuticals has submitted an IND for a registrational islet cell transplant study of tegoprubart, while reaffirming its Q4 2026 Phase 3 kidney trial start.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Latigo Biotherapeutics raises $397m IPO to fund non-opioid pain pipeline

The Thousand Oaks biotech floated on Nasdaq in August 2026 and published NEJM data on its lead NaV 1.8 inhibitor onzotrigine in acute pain.
The Thousand Oaks biotech floated on Nasdaq in August 2026 and published NEJM data on its lead NaV 1.8 inhibitor onzotrigine in acute pain.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Biologics

Newron completes ENIGMA-TRS 1 screening with 12-week data due Q1 2027

Newron Pharmaceuticals has finished screening for its 600-patient Phase 3 trial of evenamide in treatment-resistant schizophrenia, with topline results expected early
Newron Pharmaceuticals has finished screening for its 600-patient Phase 3 trial of evenamide in treatment-resistant schizophrenia, with topline results expected early
The Biotech Times Editorial Team  · 
Pharmaceuticals
Bioprocessing
Biologics

WuXi TIDES maps the path for oligonucleotides beyond the liver

WuXi AppTec argues that extrahepatic oligonucleotide delivery requires tissue-specific strategies, not a single universal technology.
WuXi AppTec argues that extrahepatic oligonucleotide delivery requires tissue-specific strategies, not a single universal technology.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Genomics

Stoke and Biogen present 4-year zorevunersen data at EEC

Four-year open-label extension data showed durable seizure reductions and cognitive gains in Dravet syndrome; Phase 3 readout is expected in Q3 2027.
Four-year open-label extension data showed durable seizure reductions and cognitive gains in Dravet syndrome; Phase 3 readout is expected in Q3 2027.
The Biotech Times Editorial Team  · 
Pharmaceuticals
Medical Devices
Diagnostics

PRF Technologies clears IND for OcuRing-K Phase II cataract trial

The Israel-based dual-business company reported FDA IND clearance for its intraocular drug-delivery ring and positive preclinical data for its non-opioid pain
The Israel-based dual-business company reported FDA IND clearance for its intraocular drug-delivery ring and positive preclinical data for its non-opioid pain
The Biotech Times Editorial Team  · 
Biologics
Regulatory Science

Vaxcyte hires CMO and CLO as VAX-31 readout moves to October

Vaxcyte has appointed two senior executives and narrowed its OPUS-1 Phase 3 topline data window to end of October 2026.
Vaxcyte has appointed two senior executives and narrowed its OPUS-1 Phase 3 topline data window to end of October 2026.
The Biotech Times Editorial Team  · 
Subscribe to